Executive Profile: Luciano Rossetti, chief cartographer for Merck Serono's R&D roadmap
This article was originally published in Scrip
Dr Luciano Rossetti was appointed global head of R&D at Merck Serono in July 2014, moving over from Merck & Co, where he had been senior vice-president of late stage development. Before joining Merck & Co [Merck Sharp & Dohme/MSD] as franchise head for diabetes and obesity in 2006, he had had a long and distinguished career in academia, focused on diabetes research in particular. A native of Naples, he moved to the US after completing medical training in Italy. He talked to Scrip's Eleanor Malone about leadership, pipeline pruning, switching careers and more.
You may also be interested in...
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.